STOCK TITAN
  1. Home
  2. News
  3. FENC

Fennec Pharmaceuticals Inc - FENC STOCK NEWS

Welcome to our dedicated news page for Fennec Pharmaceuticals (Ticker: FENC), a resource for investors and traders seeking the latest updates and insights on Fennec Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Fennec Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Fennec Pharmaceuticals's position in the market.

News
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Fennec Pharmaceuticals Inc. reported robust PEDMARK® sales in 2023, achieving $21.3 million in net product sales, with a significant licensing agreement for PEDMARQSI™ in Europe, Australia, and New Zealand. The company's pro forma cash balance exceeded $55 million, showcasing financial strength. Despite positive revenue growth, the company faced challenges with increased operating expenses and a net loss for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024
Rhea-AI Summary
Fennec Pharmaceuticals Inc. will release its full year and fourth quarter 2023 financial results on March 21, 2024. A conference call and webcast will follow to discuss the Company's financial and business performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
conferences earnings
-
News
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Rhea-AI Summary
Fennec Pharmaceuticals Inc. and Norgine enter an exclusive licensing agreement for PEDMARQSI®, the first approved therapy in EU and UK for reducing cisplatin-induced hearing loss in pediatric patients. Fennec to receive €40M upfront, up to €210M in milestones, and royalties. PEDMARQSI holds significant market potential with approvals in EU and UK based on Phase 3 trial data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.37%
Tags
none
News
Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results
Rhea-AI Summary
FENC anticipates net revenues of $9.2 to $9.7 million for the fourth quarter of 2023, with full-year results to be disclosed soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
earnings
-
News
FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin
Rhea-AI Summary
Fennec Pharmaceuticals Inc. announced that the U.S. FDA issued a public reminder to healthcare providers about the non-substitutability of PEDMARK with other sodium thiosulfate products. The FDA highlighted potential health risks associated with such substitutions, emphasizing the unique characteristics of PEDMARK. This communication aims to protect pediatric patients with localized, non-metastatic solid tumors from ototoxicity linked to cisplatin treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Fennec Announces Incremental $5 Million Investment from Petrichor
Rhea-AI Summary
Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX) announced the third closing of $5 million senior secured promissory notes under the existing agreement with Petrichor, amending it to provide access to up to $15 million of additional financing through December 31, 2024. The investment supports global PEDMARK® rollout, market expansion into the Adolescent and Young Adult (AYA) Patient Population, and strategic discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
News
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX) announces participation in upcoming conferences and one-on-one investor meetings. The company will be presenting at the Jefferies London Healthcare Conference and hosting investor meetings at the Craig Hallum Alpha Select Conference on November 16, 2023. The company's flagship product, PEDMARK®, is the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.19%
Tags
conferences
-
News
Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Fennec Pharmaceuticals Inc. reported net product revenue of $6.5 million in the third quarter, a 96% increase compared to the second quarter. The company's PEDMARK® drug addresses a significant unmet medical need in the pediatric oncology community. They also received approval for PEDMARQSI in the U.K. and are preparing for its launch in Europe. Cash and cash equivalents were $12.4 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.36%
Tags
earnings
-
News
Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023
Rhea-AI Summary
Fennec Pharmaceuticals Inc. will release its Q3 2023 financial results on November 6, 2023. The company is hosting a conference call and webcast to discuss the results. The conference call details can be accessed through the provided link, and the webcast will be available on the company's website. A webcast replay will be archived for thirty days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences earnings
News
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Fennec Pharmaceuticals to participate in upcoming conferences and host investor meetings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.13%
Tags
conferences
Stock FENC logo
Fennec Pharmaceuticals Inc

Nasdaq:FENC

FENC Rankings

#3532 Ranked by Market Cap
#3466 Ranked by Stock Gains
N/A Ranked by Dividends

FENC Stock Data

287.87M
15.29M
16.56%
55.03%
6.69%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Durham

About FENC

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.